Erythrovirus B19 infection in acquired immunodeficiency syndrome: Screening by histopathology, immunohistochemistry, and in situ hybridization

Memorias do Instituto Oswaldo Cruz

Volumn 101, Issue 4, 2006, Pages 407-414

  Setúbal, Sérgio ^a   De Oliveira, Solange Artimos ^a   Pires, Andréia Rodrigues Cordovil ^a   Da Fonseca, Eliene Carvalho ^a   Camacho, Luiz Antônio Bastos ^b   Seródio, Ana Cristina Freire ^a   Do Nascimento, Jussara Pereira ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Chronic immunodeficiency; Parvovirus B19 anemia

Indexed keywords

ERYTHROVIRUS; PARVOVIRUS;

EID: 33747132991     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762006000400011     Document Type: Article

References (42)

1. Abkowitz JL, Brown KE, Wood RW, Kovach NL, Green SW, Young NS 1997. Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis 176: 269-273.
2. Abramson JH, Gahlinger PM 2001. Computer Programs for Epidemiologists: PEPI Version 4.0, Sagebrush Press, Salt Lake City.
3. Aguiar FS, Lopes DP, Bazin AR, Setúbal S, Cohen BJ, Nascimento JP 2001. Human parvovirus B19 infection in HIV-positive patients. Rev Soc Bras Med Trop 34: 239-242.
4. Anderson MJ, Kidd IM, Jones SE, Pattison JR, Grieco MH, Lange M, Buimovici-Klein E, Cooper LZ 1985. Parvovirus infection and the acquired immunodeficiency syndrome. Ann Intern Med 102: 275.
5. Barretto Netto M, Vilar EA, Andrade LM, Silva RC, Neves MI 1988. O padrão lesional da medula óssea na imunodeficiência adquirida. Rev Inst Med Trop São Paulo 30: 253-258.
6. Brown KE 1997. Human parvovirus B19 epidemiology and clinical manifestations. In LJ Anderson, NS Young (eds), Human Parvovirus B19. Monographs in Virology, Vol. 20, Karger, Basel, p. 42-60.
7. Chen MY, Hung CC, Fang CT, Hsieh SM 2001. Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy. Clin Infect Dis 32: 1361-1365.
8. Chernak E, Dubin G, Henry D, Naides SJ, Hodinka RL, MacGregor RR, Friedman HM 1995. Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis 20: 170-173.
9. Chrystie IL, Almeida JD, Welch J 1990. Electron microscopic detection of human parvovirus (B19) in a patient with HIV infection. J Med Virol 30:249-252.
10. Crook TW, Rogers BB, McFarland RD, Kroft SH, Muretto P, Hernandez JA, Latimer MJ, McKenna RW 2000. Unusual bone marrow manifestations of parvovirus B19 infection in immunocompromised patients. Hum Pathol 31: 161-168.
11. de Mayolo JA, Temple JD 1990. Pure red cell aplasia due to parvovirus B19 infection in a man with HIV infection. South Med J 83: 1480-1481.
12. Fleiss JL 1973. Statistical Methods for Rates and Proportions, Wiley, New York.
13. Frickhofen N, Abkowitz JL, Safford M, Berry JM, Antunez-de-Mayolo J, Astrow A, Cohen R, Halperin I, King L, Mintzer D 1990. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Int Med 113: 926-933.
14. Garcia MM 1996. La medula ósea (MO) en la infección por el virus de la inmunodeficiencia humana (VIH): La MO en la etiopatogenia de las alteraciones hematológicas asociadas a la infección por el VIH. Sangre 41: 221-230.
15. Gottlieb F, Deutsch J 1992. Red cell aplasia responsive to immunoglobulin therapy as initial manifestation of human immunodeficiency virus infection. Am J Med 92: 331-333.
16. Griffin TC, Squires JE, Timmons CF, Buchanan GR 1991. Chronic human parvovirus B19-induced erythroid hypoplasia as the initial manifestation of human immunodeficiency virus infection. J Pediatr 118: 899-901.
17. Gyllensten K, Sonnerborg A, Jorup-Ronstrom C, Halvarsson M, Yun Z 1994. Parvovirus B19 infection in HIV-1 infected patients with anemia. Infection 22: 356-358.
18. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A 2002. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol 40: 933-936.
19. Jordan JA, Penchansky L 1995. Diagnoses of human parvovirus B19-induced anemia: correlation of bone marrow morphology with molecular diagnosis using PCR and immunocytochemistry. Cell Vision 2: 279-282.
20. Koduri PR 1998. Novel cytomorphology of the giant proerythroblasts of parvovirus B19 infection. Am J Hematol 58: 95-99.
21. Krause JR, Penchansky L, Knisely AS 1992. Morphological diagnosis of parvovirus B19 infection. A cytopathic effect easily recognized in air-dried, formalin-fixed bone marrow smears stained with hematoxylin-eosin or Wright-Giemsa. Arch Pathol Lab Med 116: 178-180.
22. Liu W, Ittmann M, Liu J, Schoentag R, Tierno P, Greco MA, Sidhu G, Nierodzik M, Wieczorek R 1997. Human parvovirus B19 in bone marrows from adults with acquired immunodeficiency syndrome: a comparative study using in situ hybridization and immunohistochemistry. Hum Pathol 28: 760-766.
23. Maniatis T, Fritsch EF, Sambrook J 1982. Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, New York.
24. Mitchell SA, Welch JM, Weston-Smith S, Nicholson F, Bradbeer CS 1990. Parvovirus infection and anaemia in a patient with AIDS: case report. Genitourin Med 66: 95-96.
25. Morey AL, O'Neill HJ, Coyle PV, Fleming KA 1992. Immunohistological detection of human parvovirus B19 in formalin-fixed, paraffin-embedded tissues. J Pathol 166: 105-108.
26. Musiani M, Zerbini M, Gentilomi G, Rodorigo G, De Rosa V, Gibellini D, Venturoli S, Gallinella G 1995. Persistent B19 parvovirus infections in haemophilic HIV-1 infected patients. J Med Virol 46: 103-108.
27. Naides SJ, Howard EJ, Swack NS, True CA, Stapleton JT 1993. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 168: 101-105.
28. Nascimento JP, Hallam NF, Mori J, Field AM, Clewley JP, Brown KE, Cohen BJ 1991. Detection of. B19 parvovirus in human fetal tissues by in situ hybridisation. J Med Virol 33: 77-82.
29. Nolan RC, Chidlow G, French MA 2003. Parvovirus B19 encephalitis presenting as immune restoration disease after highly active antiretroviral therapy for human immunodeficiency virus infection. Clin Infect Dis 36: 1191-1194.
30. Noronha JT, Martins JC, Leal A, Pone MVS, Campos JMS, Barros ACMW, Garrido JRP, Pone SM, Nascimento JP 2005. Parvovirus B19 associado ao HIV: relato de caso. Rev Soc Bras Med Trop 38: 285.
31. Ozawa K, Kurtzman G, Young N 1986. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 233: 883-886.
32. Pereira RF, Paula WN, Cubel RC, Nascimento JP 2001. Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection. Mem Inst Oswaldo Cruz 96: 507-513.
33. Porter HJ, Heryet A, Quantrill AM, Fleming KA 1990. Combined non-isotopic in situ hybridisation and immunohistochemistry on routine paraffin wax embedded tissue: identification of cell type infected by human parvovirus and demonstration of cytomegalovirus DNA and antigen in renal infection. J Clin Pathol 43: 129-132.
34. Scapellato PG, Palumbo AM, Del Valle S 2000. Improvement of anemia induced by parvovirus B19 in a patient with AIDS after combined antiretroviral therapy. Mayo Clin Proc 75: 215-216.
35. Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE, Mohamed R 1981. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 2(8247): 595-597.
36. Setúbal S, Cárdias CAS, Oliveira SA, Nascimento JP 2004. Viremic blood found in a season of high human parvovirus B19 activity in Niterói, Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 99: 95-99.
37. Setúbal S, Jorge-Pereira MC, de Sant'Anna AL, Oliveira SA, Bazin AR, Nascimento JP 2003. Clinical presentation of parvovirus B19 infection in HIV-infected patients with and without AIDS. Rev Soc Bras Med Trop 36: 299-302.
38. Soderlund-Venermo MK, Hokynar K, Nieminen J, Rautakorpi H, Hedman K 2002. Persistence of human parvovirus B19 in human tissues. Pathol Biol (Paris) 50: 307-316.
39. Valeur-Jensen AK, Pedersen CB, Westergaard T, Jensen IP, Lebech M, Andersen PK, Aaby P, Pedersen BN, Melbye M 1999. Risk factors for parvovirus B19 infection in pregnancy. JAMA 281: 1099-1105.
40. van Elsacker-Neile AM, Kroon FP, van der Ende ME, Salimans MM, Spaan WJ, Kroes AC 1996. Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. Clin Infect Dis 23: 1255-1260.
41. Vernazza PL, Pfister LA, Siegl G, Cassinotti P 1996. High seroprevalence of parvovirus B19 among patients infected with human immunodeficiency virus. Clin Infect Dis 22: 198-199.
42. Young NS, Brown KE 2004. Parvovirus B19. New Eng J Med 350: 589-597.